Sapropterin (kuvan) (DrugBank: Sapropterin)
5 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 0 |
| 86 | Pulmonary arterial hypertension | 0 |
| 124 | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy | 0 |
| 240 | Phenylketonuria | 1 |
| 299 | Cystic fibrosis | 0 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00730080 (ClinicalTrials.gov) | July 2008 | 1/8/2008 | Sapropterin in Individuals With Phenylketonuria | Effects of Sapropterin on Brain and Cognition in Individuals With Phenylketonuria | Phenylketonuria | Drug: Sapropterin (Kuvan) | Washington University School of Medicine | BioMarin Pharmaceutical;University of Missouri-Columbia | Completed | 6 Years | 50 Years | All | 45 | United States |